NasdaqGS - Nasdaq Real Time Price USD

Werewolf Therapeutics, Inc. (HOWL)

1.1100

0.0000

(0.00%)

At close: May 16 at 4:00:01 PM EDT

1.0800

-0.03

(-2.70%)

After hours: May 16 at 7:59:32 PM EDT

Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit

WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced Sameer Chopra, M.D., Ph.D., Vice President of Clinical Development, will speak during the Hanson Wade Cytokine-Based Drug Development Sum

GlobeNewswire 3 days ago

HOWL
0.00%
Werewolf Therapeutics First Quarter 2025 Earnings: US$0.40 loss per share (vs US$0.39 loss in 1Q 2024)

Werewolf Therapeutics ( NASDAQ:HOWL ) First Quarter 2025 Results Key Financial Results Net loss: US$18.1m (loss widened...

Simply Wall St. 6 days ago

HOWL
0.00%
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

– WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year – – First patient dosed in the Phase 1b/2 clinical trial of WTX-330, seeking to build on the clinical activity and tolerability demonstrated in the recently completed WTX-330 first-in-human Phase 1 trial – – Company announces development of its proprietary INDUCER™ T cell engager molecules; development candidate targeted by the end of the second quarter of 2025 – – Updated

GlobeNewswire 8 days ago

HOWL
0.00%
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

- Data reveal WTX-921 is efficacious in a mouse colitis model, resulting in reduced tissue damage and inflammatory cytokine production - - Findings offer a more detailed understanding of WTX-921’s anti-inflammatory impact on the immune landscape in the inflamed colon - WATERTOWN, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutic

GlobeNewswire 11 days ago

HOWL
0.00%
Werewolf Therapeutics to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that management will participate in the following upcoming investor conferences in the month of May: The Citizens Life Sciences Conferenc

GlobeNewswire 11 days ago

HOWL
0.00%
Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline

Werewolf Therapeutics (HOWL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 21 days ago

HOWL
0.00%

TARS
Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced the appointment of Steven Bloom as Chief Business Officer. Mr. Bloom brings more than 35 years of experience in the life sciences indus

GlobeNewswire 29 days ago

HOWL
0.00%
Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

WATERTOWN, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer and Randi Isaacs, M.D., Chief Medical Officer, both of Werewolf Th

GlobeNewswire last month

HOWL
0.00%
Werewolf Therapeutics Full Year 2024 Earnings: EPS Misses Expectations

Werewolf Therapeutics ( NASDAQ:HOWL ) Full Year 2024 Results Key Financial Results Net loss: US$70.5m (loss widened by...

Simply Wall St. 2 months ago

HOWL
0.00%
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

– Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half and the second half of 2025, respectively – – Plan to meet with the FDA in the second half of 2025 to discuss potential registrational pathways for both monotherapy and combination therapy for WTX-124 in select indications – – Interim data from Phase 1/1b clinical trial of WTX-124 as monotherapy and

GlobeNewswire 2 months ago

HOWL
0.00%
Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference

WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Were

GlobeNewswire 2 months ago

HOWL
0.00%
Pacira (PCRX) Tops Q4 Earnings Estimates

Pacira (PCRX) delivered earnings and revenue surprises of 5.81% and 0.03%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

HOWL
0.00%
Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors

WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and immunological diseases, today announced the appointment of Anil Singhal, Ph.D., President and Chief Executive Officer of Trishula Therapeutics, as a member of its board of directors. “I am thrilled to join Werewolf’s

GlobeNewswire 2 months ago

HOWL
0.00%
Oramed Pharmaceuticals And 2 Other US Penny Stocks To Watch

As Wall Street navigates the complexities of tariffs and Federal Reserve Chair Jerome Powell's testimony, the U.S. stock market remains a mixed bag with indices showing varied performance. Amid these broader economic discussions, penny stocks continue to capture investor interest by offering potential growth opportunities at lower price points. While often associated with smaller or newer companies, these stocks can present compelling prospects when backed by strong financials and solid...

Simply Wall St. 3 months ago

ORMP

HOWL
0.00%

VSTA
Werewolf Therapeutics provides business update, highlights 2025 outlook

Werewolf Therapeutics (HOWL) provided a business update and outlined its strategic outlook and expected milestones for 2025. “2024 was a year of execution for Werewolf in which we reported data from both of our clinical programs, highlighting promising durable anti-tumor activity with unprecedented tolerability for cytokine therapeutics. These data reinforced our INDUKINETM design, establishing that we could reproducibly improve the therapeutic index in an outpatient setting with a potentially b

TipRanks 3 months ago

HOWL
0.00%
Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

– Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 as monotherapy expected in first half of 2025 to guide regulatory engagement on potential registrational pathways – – Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 in combination with pembrolizumab anticipated in fourth quarter of 2025 – – Initiation of Phase 1/2 dose and regimen-finding clinical trial of WTX-330 expected in first quarter of 2025 – – Cash guidance provides runway through at leas

GlobeNewswire 3 months ago

HOWL
0.00%
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference

WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werew

GlobeNewswire 5 months ago

HOWL
0.00%
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

- Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signals - - Additional preclinical data demonstrate INDUKINETM molecules’ anti-tumor potency with distinct immune activation profiles across four cytokines - WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical compan

GlobeNewswire 6 months ago

HOWL
0.00%
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

– Interim data from ongoing Phase 1 clinical trial of WTX-330, further characterizing tolerability and activity profile, to be presented at SITC Annual Meeting – – Monotherapy and combination expansion arms open and enrolling in ongoing Phase 1/1b clinical trial of WTX-124; initial efficacy data from monotherapy expansion arms anticipated in the first half of 2025 – – Introduced WTX-921, a promising new development candidate and first-of-its kind IL-10 INDUKINE™ molecule for the treatment of inf

GlobeNewswire 6 months ago

HOWL
0.00%
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases

WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced the addition of WTX-921, a novel IL-10 INDUKINE development candidate for Inflammatory Bowel Disease (IBD) and potentially other inflamm

GlobeNewswire 6 months ago

HOWL
0.00%

Performance Overview

Return	HOWL	S&P 500 (^GSPC)
YTD	-25.00%	+1.30%
1-Year	-77.25%	+12.48%
3-Year	-75.60%	+48.66%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Werewolf Therapeutics, Inc. (HOWL)

Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit

Werewolf Therapeutics First Quarter 2025 Earnings: US$0.40 loss per share (vs US$0.39 loss in 1Q 2024)

Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline

Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Werewolf Therapeutics Full Year 2024 Earnings: EPS Misses Expectations

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference

Pacira (PCRX) Tops Q4 Earnings Estimates

Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors

Oramed Pharmaceuticals And 2 Other US Penny Stocks To Watch

Werewolf Therapeutics provides business update, highlights 2025 outlook

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference

Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases

Performance Overview